tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk tirzepatide cardiovascular outcomes trial 2024

Finerenone is recommended as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. Kerendia can cause some mild side effects: Low blood pressure

Accessing GLP-1 Therapy Without Breaking Your Budget The total monthly investment for sustainable weight loss through PlexusDx ranges from $129/mo to $349/mo depending on the formulation selected, compared to the $900$1,500 patients typically pay for brand-name GLP-1 injections

After this initial month, it is recommended to increase the dose to 7 mg of Rybelsus once daily3

The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment